HRP20120882T1 - Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf signalne kaskade - Google Patents

Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf signalne kaskade Download PDF

Info

Publication number
HRP20120882T1
HRP20120882T1 HRP20120882TT HRP20120882T HRP20120882T1 HR P20120882 T1 HRP20120882 T1 HR P20120882T1 HR P20120882T T HRP20120882T T HR P20120882TT HR P20120882 T HRP20120882 T HR P20120882T HR P20120882 T1 HRP20120882 T1 HR P20120882T1
Authority
HR
Croatia
Prior art keywords
seq
antibody
antigen
binding fragment
ngf
Prior art date
Application number
HRP20120882TT
Other languages
English (en)
Inventor
Kenneth D. Wild Jr.
James J. S. Treanor
Haichun Huang
Heather Inoue
Tie J. Zhang
Frank Martin
Original Assignee
Amgen Inc.
Medarex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Medarex, Inc. filed Critical Amgen Inc.
Publication of HRP20120882T1 publication Critical patent/HRP20120882T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Claims (21)

1. Izolirano humano antitijelo ili antigen vezujući fragment istog koji se specifično vezuje na NGF, a koji se sastoji od: a) okvirnih (FR) regija humanog teškog lanca, s tim da se varijabilna regija humanog teškog lanca sastoji od CDR1 (SEQ ID NO: 22), CDR2 (SEQ ID NO: 18) i CDR3 (SEQ ID NO: 14) od SEQ ID NO: 10; i b) okvirnih (FR) regija humanog lakog lanca, s tim da se varijabilna regija humanog lakog lanca sastoji od CDR1 (SEQ ID NO: 24), CDR2 (SEQ ID NO: 20) i CDR3 (SEQ ID NO: 16) od SEQ ID NO: 12.
2. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da se teški lanac sastoji od varijabilne regije teškog lanca čiji je slijed SEQ ID NO: 10, a laki lanac se sastoji od varijabilne regije lakog lanca čiji je slijed SEQ ID NO: 12.
3. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da teški lanac obuhvaća varijabilnu regiju i konstantnu regiju, naznačen time da varijabilna regija ima slijed SEQ ID NO: 10.
4. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da laki lanac obuhvaća varijabilnu regiju i konstantnu regiju, naznačen time da varijabilna regija ima slijed SEQ ID NO: 12.
5. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44.
6. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da antitijelo obuhvaća teški lanac čiji su sljedovi SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42 ili SEQ ID NO: 43.
7. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44, i teški lanac čiji su sljedovi SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42 ili SEQ ID NO: 43.
8. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 7, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44 i teški lanac čiji je slijed SEQ ID NO: 40.
9. Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1-8, naznačen time da se antitijelo ili antigen vezujući fragment odvaja od humanog NGF polipeptida s KD (konstantno disocijacije) od 4 x 10-12 M.
10. Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1-8, naznačen time da antitijelo ili antigen vezujući fragment neutralizira humanu NFG indukciju ekspresije vaniloidnog receptora-1 (VR1) u DRG neuronima uz IC50 od 0,5 x 10-9 M.
11. Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1-10, naznačen time da su teški lanac i laki lanac povezani fleksibilnom poveznicom, čime nastaje antitijelo s jednim lancem.
12. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 11, koje je antitijelo s jednim lancem varijabilne domene (Fv).
13. Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1 do 10, koji je: a) antitijelo s Fab fragmentom; b) antitijelo s Fab' fragmentom; ili c) antitijelo s (Fab')2 fragmentom.
14. Farmaceutski pripravak koji se sastoji od farmaceutski prihvatljivog nositelja i terapeutski učinkovite količine antitijela ili antigen vezujućeg fragmenta istog prema jednom od zahtjeva 1 do 13.
15. Metoda detekcije NGF-a u biološkom uzorku, koja obuhvaća: a) dovođenje uzorka u kontakt s antitijelom prema jednom od zahtjeva 1 do 13, pod uvjetima koji omogućavaju vezivanje antitijela na NGF; i b) mjerenje razine vezanih antitijela u uzorku.
16. Molekula nukleinske kiseline koja kodira antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1 do 13.
17. Molekula nukleinske kiseline prema zahtjevu 16, naznačena time da nukleinska kiselina sadrži: a) SEQ ID NO: 9; i SEQ ID NO: 11; ili b) SEQ ID NO: 21, SEQ ID NO: 17, SEQ ID NO: 13; i SEQ ID NO: 23, SEQ ID NO: 19, SEQ ID NO: 15.
18. Izolirana stanica domaćin koja sadrži nukleinsku kiselinu prema zahtjevu 16 ili 17.
19. Izolirana stanična linija koja proizvodi antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1 do 13.
20. Antitijelo ili antigen vezujući fragment istog prema jednom od zahtjeva 1 do 13 ili farmaceutski prihvatljive soli antitijela ili antigen vezujućeg fragmenta istog za korištenje u liječenju poremećaja boli ili stanja uzrokovanog pojačanom ekspresijom NGF-a ili povećanom osjetljivošću na NGF, naznačen time da su poremećaj ili stanje akutna bol, zubobolja, bol od ozljeda, bol nakon kirurškog zahvata ili bol kao posljedica: amputacije ili apscesa, kauzalgije, demijelinizirajuće bolesti, trigeminalne neuralgije, raka, kroničnog alkoholizma, moždanog udara, talamičnog sindroma, dijabetesa, sindroma stečene imunodeficijencije („SIDA“), toksina, kemoterapije, obične glavobolje, migrene, cluster glavobolje, mješovitih vaskularnih i nevaskularnih sindroma, tenzijske glavobolje, opće upale, artritisa, reumatskih bolesti, lupusa, osteoartritisa, fibromijalgije, upalnih crijevnih poremećaja, sindroma prenadraženog crijeva, upalnih poremećaja oka, upalnih poremećaja mjehura ili nestablinog mjehura, psorijaze, kožnih tegoba s upalnim komponentama, opeklina od sunca, karditisa, dermatitisa, miozitisa, neuritisa, kolagen-vaskularne bolesti, kroničnih upalnih stanja, upale i povezane hiperalgezije i alodinije, neuropatije i povezane hiperalgezije i alodinije, dijabetske neuropatije, deaferentacijskih sindroma, astme, oštećenja ili disfunkcije tkiva epitela, herpes simplexa, poremećaja visceralne pokretljivosti u respiratornoj, genitourinarnoj, gastrointestinalnoj i vaskularnoj regiji, rana, opeklina, alergijskih reakcija kože, pruritisa, vitiliga, opći poremećaji probavnog sustava, kolitisa, čira na želucu, čira na dvanaestercu, vazomotornog ili alergijskog rinitisa, poremećaja bronhija, dismenoreje, dispepsije, gastroezofagealnog refluksa, upale gušterače ili visceralgije.
21. Korištenje farmaceutski učinkovite količine antitijela ili antigen vezujućeg fragmenta istog prema jednom od zahtjeva 1 do 13 za proizvodnju lijeka za liječenje poremećaja boli ili stanja uzrokovanog pojačanom ekspresijom NGF-a ili povećanom osjetljivošću na NGF, naznačen time da su poremećaj ili stanje akutna bol, zubobolja, bol od ozljeda, bol nakon kirurškog zahvata ili bol kao posljedica: amputacije ili apscesa, kauzalgije, demijelinizirajuće bolesti, trigeminalne neuralgije, raka, kroničnog alkoholizma, moždanog udara, talamičnog sindroma, dijabetesa, sindroma stečene imunodeficijencije („SIDA“), toksina, kemoterapije, obične glavobolje, migrene, cluster glavobolje, mješovitih vaskularnih i nevaskularnih sindroma, tenzijske glavobolje, opće upale, artritisa, reumatskih bolesti, lupusa, osteoartritisa, fibromijalgije, upalnih crijevnih poremećaja, sindroma prenadraženog crijeva, upalnih poremećaja oka, upalnih poremećaja mjehura ili nestablinog mjehura, psorijaze, kožnih tegoba s upalnim komponentama, opeklina od sunca, karditisa, dermatitisa, miozitisa, neuritisa, kolagen-vaskularne bolesti, kroničnih upalnih stanja, upale i povezane hiperalgezije i alodinije, neuropatije i povezane hiperalgezije i alodinije, dijabetske neuropatije, deaferentacijskih sindroma, astme, oštećenja ili disfunkcije tkiva epitela, herpes simplexa, poremećaja visceralne pokretljivosti u respiratornoj, genitourinarnoj, gastrointestinalnoj i vaskularnoj regiji, rana, opeklina, alergijskih reakcija kože, pruritisa, vitiliga, opći poremećaji probavnog sustava, kolitisa, čira na želucu, čira na dvanaestercu, vazomotornog ili alergijskog rinitisa, poremećaja bronhija, dismenoreje, dispepsije, gastroezofagealnog refluksa, upale gušterače ili visceralgije.
HRP20120882TT 2003-07-15 2012-10-31 Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf signalne kaskade HRP20120882T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48743103P 2003-07-15 2003-07-15
PCT/US2004/022876 WO2005019266A2 (en) 2003-07-15 2004-07-15 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors

Publications (1)

Publication Number Publication Date
HRP20120882T1 true HRP20120882T1 (hr) 2013-02-28

Family

ID=34215825

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20060033AA HRP20060033B1 (hr) 2003-07-15 2006-01-24 Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf rute
HRP20120882TT HRP20120882T1 (hr) 2003-07-15 2012-10-31 Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf signalne kaskade

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20060033AA HRP20060033B1 (hr) 2003-07-15 2006-01-24 Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf rute

Country Status (31)

Country Link
US (7) US7601818B2 (hr)
EP (2) EP2364728A1 (hr)
JP (8) JP4489077B2 (hr)
CN (3) CN1849138B (hr)
AR (2) AR045056A1 (hr)
AU (2) AU2004267030B2 (hr)
BR (1) BRPI0412567B1 (hr)
CA (1) CA2534585C (hr)
CY (1) CY1113167T1 (hr)
DK (1) DK1648509T3 (hr)
EA (2) EA013614B1 (hr)
ES (1) ES2392954T3 (hr)
GE (3) GEP20104887B (hr)
HK (2) HK1088534A1 (hr)
HR (2) HRP20060033B1 (hr)
IL (5) IL173076A (hr)
MA (1) MA27952A1 (hr)
ME (2) MEP31508A (hr)
MX (2) MXPA06000583A (hr)
NO (1) NO20060381L (hr)
NZ (3) NZ599196A (hr)
PL (1) PL1648509T3 (hr)
PT (1) PT1648509E (hr)
RS (2) RS52332B (hr)
SG (1) SG10201404744RA (hr)
SI (1) SI1648509T1 (hr)
TN (1) TNSN06010A1 (hr)
TW (4) TWI503328B (hr)
UA (2) UA115960C2 (hr)
WO (1) WO2005019266A2 (hr)
ZA (1) ZA200600847B (hr)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0367170A (ja) * 1989-08-04 1991-03-22 Nippon Steel Corp 金属試料中の微量炭素，硫黄，燐の分析方法
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
DE602004030535D1 (de) 2003-02-19 2011-01-27 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
TWI503328B (zh) * 2003-07-15 2015-10-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ES2338344T3 (es) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
US7725178B2 (en) * 2004-06-30 2010-05-25 Cedars-Sinai Medical Center Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
BRPI0606933B8 (pt) * 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
US8008259B2 (en) 2005-11-07 2011-08-30 Copenhagen University, Techtrans Unit Neurotrophin-derived peptide sequences
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
US8207304B2 (en) * 2006-10-19 2012-06-26 Csl Limited Antibody antagonists of interleukin-13 receptor α1
US8247537B2 (en) * 2006-11-15 2012-08-21 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
WO2008103475A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
AU2012216653B2 (en) * 2007-08-10 2013-12-12 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JP5632744B2 (ja) * 2007-08-10 2014-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト神経成長因子に対する高親和性ヒト抗体
CA2698103A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
CN102216329A (zh) * 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
US8034344B2 (en) * 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TW201022288A (en) * 2008-06-30 2010-06-16 Novo Nordisk As Anti-human interleukin-20 antibodies
CN102159204B (zh) 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
EP2350075B1 (en) 2008-09-22 2014-03-05 Array Biopharma, Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
PT2350071E (pt) 2008-10-22 2014-04-11 Array Biopharma Inc Compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da cinase trk
CN102292338B (zh) * 2008-12-08 2016-09-28 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
US10471212B2 (en) * 2009-10-29 2019-11-12 W. L. Gore & Associates, Inc. Silicone free drug delivery devices
US9597458B2 (en) 2009-10-29 2017-03-21 W. L. Gore & Associates, Inc. Fluoropolymer barrier materials for containers
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
HRP20150963T4 (hr) 2010-06-07 2023-12-08 Amgen Inc. Uređaj za primjenu lijeka
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US11612697B2 (en) 2010-10-29 2023-03-28 W. L. Gore & Associates, Inc. Non-fluoropolymer tie layer and fluoropolymer barrier layer
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20190112175A (ko) * 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
US10092706B2 (en) 2011-04-20 2018-10-09 Amgen Inc. Autoinjector apparatus
WO2013009582A1 (en) 2011-07-12 2013-01-17 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2013022083A1 (ja) 2011-08-11 2013-02-14 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
PL3045187T3 (pl) 2011-10-14 2019-09-30 Amgen Inc. Wstrzykiwacz i sposób montażu
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
EP2858501A4 (en) 2012-05-22 2015-12-09 Merck Sharp & Dohme TRK-A KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3456741B1 (en) 2012-05-22 2020-12-16 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
ES2951440T3 (es) 2012-11-21 2023-10-20 Amgen Inc Dispositivo de administración de fármacos
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
CA2904725C (en) 2013-03-15 2022-04-12 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
JP6768501B2 (ja) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド 薬物カセット、自動注入機、および自動注入機システム
CN113559363B (zh) 2013-03-22 2023-10-31 美国安进公司 注射器及装配方法
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
MX2016002870A (es) 2013-09-05 2017-02-23 Amgen Inc Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015061386A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Injector and method of assembly
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
MX2016008667A (es) * 2013-12-30 2017-02-02 Epimab Biotherapeutics Inc Inmunoglobulina con fab en tandem y usos de esta.
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
US9346788B2 (en) 2014-02-05 2016-05-24 VM Oncology, LLC TrkA receptor tyrosine kinase antagonists and uses thereof
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
WO2015187793A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Drug delivery system and method of use
WO2016035052A1 (en) * 2014-09-05 2016-03-10 Nvip Pty Ltd Anti-nerve growth factor antibodies for treating itching
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
NZ731909A (en) 2014-11-16 2023-11-24 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ES2898469T3 (es) 2014-12-19 2022-03-07 Amgen Inc Dispositivo de administración de medicamentos con sensor de proximidad
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2016146730A1 (en) * 2015-03-19 2016-09-22 Neuheart S.R.L. PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
RU2729825C2 (ru) 2015-05-22 2020-08-12 Астеллас Фарма Инк. Новый fab-фрагмент антитела к человеческому ngf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
SI3334747T1 (sl) 2015-08-13 2024-02-29 Amgen Inc. Globinsko nabito filtriranje proteinov, ki vežejo antigen
CN108135999B (zh) 2015-08-13 2022-05-31 马萨诸塞大学 针对狂犬病的人抗体及其用途
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
AU2017214692B2 (en) 2016-02-06 2021-11-04 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CR20180501A (es) 2016-04-04 2019-04-05 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
PT3458456T (pt) 2016-05-18 2020-12-07 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
SG11201810763TA (en) 2016-06-14 2018-12-28 Merck Sharp & Dohme Anti-coagulation factor xi antibodies
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
GB201614884D0 (en) * 2016-09-01 2016-10-19 Oblique Therapeutics Ab Method
GB201617002D0 (en) * 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method
KR20190064636A (ko) * 2016-10-19 2019-06-10 메디뮨 엘엘씨 항-o1 항체 및 이의 용도
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
GB201621907D0 (en) * 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
KR20240005194A (ko) 2017-03-09 2024-01-11 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
MX2019015479A (es) 2017-06-23 2020-02-20 Amgen Inc Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
JP2020527376A (ja) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
MA50614A (fr) 2017-10-06 2020-08-12 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
MA50904A (fr) 2017-11-16 2020-09-23 Amgen Inc Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
JP2021503311A (ja) 2017-11-16 2021-02-12 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
CA3093772A1 (en) 2018-03-12 2019-09-19 Zoetis Services Llc Anti-ngf antibodies and methods thereof
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
JP2022503983A (ja) 2018-10-02 2022-01-12 アムジエン・インコーポレーテツド 内力伝達を伴う薬物送達用の注入システム
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
IT201800009384A1 (it) 2018-10-11 2020-04-11 Cosmo Srl Peptide for cosmetic application
CA3112355A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
US20210346596A1 (en) 2018-10-15 2021-11-11 Amgen Inc. Platform assembly process for drug delivery device
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
JP2022545227A (ja) 2019-08-23 2022-10-26 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
CN117186219A (zh) * 2020-04-17 2023-12-08 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117050175A (zh) * 2020-04-17 2023-11-14 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN113993900B (zh) * 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
AR122141A1 (es) 2020-05-28 2022-08-17 Lilly Co Eli Inhibidor de trka
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Ampsource Biopharma Shanghai Inc. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
IL307418A (en) 2021-05-21 2023-12-01 Amgen Inc A method for optimizing a filling recipe for a drug container
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
GB2077573A (en) 1980-06-10 1981-12-23 Kangol Magnet Ltd Vehicle seat belt connection device
US4786593A (en) 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
JP2969647B2 (ja) 1988-09-14 1999-11-02 東ソー株式会社 モノクローナル抗体、それからなる阻害剤及びそれを用いた測定方法
SE465573B (sv) 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
JPH03163095A (ja) 1989-08-28 1991-07-15 Takeda Chem Ind Ltd ヒト神経成長因子の部分ペプチド、抗体およびその用途
ES2109225T3 (es) 1989-08-28 1998-01-16 Takeda Chemical Industries Ltd Anticuerpos, su produccion y uso.
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
JP3232415B2 (ja) 1990-08-29 2001-11-26 武田薬品工業株式会社 モノクローナル抗体，その製造法および用途
JPH06317587A (ja) 1990-08-31 1994-11-15 Takeda Chem Ind Ltd 抗体およびその用途
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
JPH0576384A (ja) 1991-09-20 1993-03-30 Hitachi Ltd 抗ヒト神経成長因子モノクローナル抗体
JP3519096B2 (ja) 1992-07-02 2004-04-12 武田薬品工業株式会社 モノクローナル抗体、ハイブリドーマおよびそれらの用途
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
US7322122B2 (en) 1997-01-15 2008-01-29 Draka Comteq B.V. Method and apparatus for curing a fiber having at least two fiber coating curing stages
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
SI1210115T1 (sl) * 1999-08-27 2009-12-31 Genentech Inc Doziranja za zdravljenje s protitelesi proti ErbB2
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
CA2448956C (en) 2001-05-30 2017-10-03 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
CN1571797A (zh) 2001-10-15 2005-01-26 麒麟麦酒株式会社 抗hla－dr抗体
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
ZA200502612B (en) * 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
EP1468999A1 (en) * 2003-03-20 2004-10-20 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
TWI503328B (zh) * 2003-07-15 2015-10-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
BRPI0606933B8 (pt) 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico

Also Published As

Publication number Publication date
NZ588527A (en) 2012-06-29
GEP20196963B (en) 2019-04-10
EA030259B1 (ru) 2018-07-31
RS20100555A (en) 2011-08-31
US20110040076A1 (en) 2011-02-17
IL214281A0 (en) 2011-08-31
JP2015155413A (ja) 2015-08-27
EP1648509A2 (en) 2006-04-26
CN102358903B (zh) 2017-04-26
IL173076A (en) 2015-10-29
UA97086C2 (uk) 2012-01-10
GEP20146050B (en) 2014-03-10
US20160237147A1 (en) 2016-08-18
SI1648509T1 (sl) 2012-12-31
MX341869B (es) 2016-09-06
IL173076A0 (en) 2006-06-11
EP2364728A1 (en) 2011-09-14
US20050074821A1 (en) 2005-04-07
ES2392954T3 (es) 2012-12-17
JP2012250986A (ja) 2012-12-20
CA2534585A1 (en) 2005-03-03
CA2534585C (en) 2012-02-21
HRP20060033B1 (hr) 2014-02-28
RS20060022A (en) 2008-06-05
EA201000245A1 (ru) 2010-12-30
JP2010162028A (ja) 2010-07-29
US20090155274A1 (en) 2009-06-18
US20080033157A1 (en) 2008-02-07
WO2005019266A3 (en) 2005-04-28
US20160304596A1 (en) 2016-10-20
AR045056A1 (es) 2005-10-12
EP1648509B1 (en) 2012-09-12
TWI635096B (zh) 2018-09-11
JP2017079782A (ja) 2017-05-18
HK1096310A1 (en) 2007-06-01
EA030259B8 (ru) 2018-09-28
CN102408483A (zh) 2012-04-11
MA27952A1 (fr) 2006-06-01
UA115960C2 (uk) 2018-01-25
US7601818B2 (en) 2009-10-13
MEP31508A (hr) 2010-10-10
AU2004267030A1 (en) 2005-03-03
CN1849138B (zh) 2011-11-30
HK1088534A1 (en) 2006-11-10
TW200911833A (en) 2009-03-16
TW201534621A (zh) 2015-09-16
TWI382031B (zh) 2013-01-11
ZA200600847B (en) 2007-01-31
IL241874A0 (en) 2015-11-30
TWI385180B (zh) 2013-02-11
TNSN06010A1 (en) 2007-10-03
CN1849138A (zh) 2006-10-18
US8106167B2 (en) 2012-01-31
RS52332B (en) 2012-12-31
CN102408483B (zh) 2016-06-08
EP1648509B8 (en) 2012-10-24
HRP20060033A2 (hr) 2007-04-30
JP2007537703A (ja) 2007-12-27
JP5965964B2 (ja) 2016-08-10
US7795413B2 (en) 2010-09-14
IL214280A0 (en) 2011-08-31
NZ599196A (en) 2014-01-31
JP2015042670A (ja) 2015-03-05
SG10201404744RA (en) 2014-10-30
TWI503328B (zh) 2015-10-11
BRPI0412567B1 (pt) 2017-03-21
IL214281A (en) 2016-07-31
GEP20104887B (en) 2010-02-10
TW201311721A (zh) 2013-03-16
PL1648509T3 (pl) 2013-02-28
JP2012161316A (ja) 2012-08-30
NO20060381L (no) 2006-03-22
AU2010202177B2 (en) 2013-12-12
CN102358903A (zh) 2012-02-22
US20110091476A1 (en) 2011-04-21
NZ544751A (en) 2009-05-31
EA200600254A1 (ru) 2006-12-29
MXPA06000583A (es) 2006-03-30
BRPI0412567A (pt) 2006-09-19
US8198410B2 (en) 2012-06-12
CY1113167T1 (el) 2016-04-13
WO2005019266A2 (en) 2005-03-03
EA013614B1 (ru) 2010-06-30
JP2010006812A (ja) 2010-01-14
ME02785B (me) 2012-12-31
AU2010202177A1 (en) 2010-06-17
JP5264798B2 (ja) 2013-08-14
AU2004267030B2 (en) 2010-06-17
DK1648509T3 (da) 2013-01-07
IL206823A0 (en) 2011-08-01
PT1648509E (pt) 2012-10-18
TW200513468A (en) 2005-04-16
AR075790A2 (es) 2011-04-27
JP4489077B2 (ja) 2010-06-23

Similar Documents

Publication Publication Date Title
HRP20120882T1 (hr) Humana anti-ngf neutralizirajuä†a antitijela kao selektivni inhibitori ngf signalne kaskade
JP2015042670A5 (hr)
AU2024200309A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP7454525B2 (ja) 改善された免疫グロブリン可変ドメイン
US11267884B2 (en) Antibody to human IL-1 beta
EP3581245B1 (en) Antibodies to tau and uses thereof
ES2698976T3 (es) Anticuerpo sintético de un solo dominio
ES2822431T3 (es) Polipéptidos de unión a IL-17A
EP2976104B1 (en) Anti-bag3 antibodies for therapeutic use
US11180536B2 (en) Antibodies to royalactin and uses thereof
EP3154564B1 (en) New polypeptide
CN111788230B (zh) 抗TrkA抗体
US20220363747A1 (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and il-23
US20210363265A1 (en) Multivalent receptor-clustering agonist antibody constructs
US20220064272A1 (en) Anti-tauc3 antibodies and uses thereof
Bouhaouala-Zahar et al. Immunological aspects of scorpion toxins: current status and perspectives
RU2016117140A (ru) Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
EP3177647B1 (en) Anti-herg1 antibodies
US20170253672A1 (en) Removal of monomeric targets
CN113354736B (zh) 靶向人pd-l1单克隆抗体或其抗原结合片段及其应用
CN117384290B (zh) 人源robo1结合分子及其应用
RU2774823C2 (ru) Усовершенствованные агенты, связывающие tnf
WO2024038095A1 (en) NOVEL ANTI-RGMb ANTIBODIES
CN101899416A (zh) 重组鼠骨髓瘤细胞ns0-f10及其应用
JPWO2021147829A5 (hr)